bluebird bio (NASDAQ:BLUE) Given “Neutral” Rating at Cantor Fitzgerald

bluebird bio (NASDAQ:BLUE)‘s stock had its “neutral” rating reaffirmed by analysts at Cantor Fitzgerald in a note issued to investors on Monday, Benzinga reports.

BLUE has been the subject of a number of other research reports. JPMorgan Chase & Co. downgraded bluebird bio from an “overweight” rating to a “neutral” rating in a research report on Thursday, August 15th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $4.00 target price on shares of bluebird bio in a research report on Thursday, August 15th. Barclays cut their price target on shares of bluebird bio from $8.00 to $4.00 and set an “overweight” rating on the stock in a research report on Thursday, August 15th. Bank of America lowered their target price on bluebird bio from $4.00 to $3.00 and set a “buy” rating on the stock in a research report on Thursday, August 15th. Finally, Robert W. Baird reduced their price target on bluebird bio from $7.00 to $6.00 and set an “outperform” rating for the company in a research report on Thursday, August 15th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, bluebird bio currently has an average rating of “Hold” and an average price target of $4.74.

bluebird bio Price Performance

Shares of bluebird bio stock opened at $0.61 on Monday. The firm has a market cap of $66.70 million, a price-to-earnings ratio of -0.82 and a beta of 0.75. bluebird bio has a one year low of $0.52 and a one year high of $5.53. The stock’s 50-day moving average is $0.89 and its 200-day moving average is $1.02.

Institutional Investors Weigh In On bluebird bio

Hedge funds have recently added to or reduced their stakes in the business. Ghisallo Capital Management LLC acquired a new stake in shares of bluebird bio during the 4th quarter worth about $4,347,000. Vestal Point Capital LP bought a new stake in shares of bluebird bio during the fourth quarter worth approximately $2,967,000. Vanguard Group Inc. grew its position in shares of bluebird bio by 19.6% in the first quarter. Vanguard Group Inc. now owns 10,498,460 shares of the biotechnology company’s stock valued at $13,438,000 after purchasing an additional 1,723,081 shares during the last quarter. HBK Investments L P bought a new position in shares of bluebird bio during the fourth quarter worth approximately $2,070,000. Finally, AQR Capital Management LLC increased its stake in shares of bluebird bio by 315.3% during the second quarter. AQR Capital Management LLC now owns 1,334,519 shares of the biotechnology company’s stock worth $1,223,000 after purchasing an additional 1,013,144 shares during the period. Institutional investors and hedge funds own 87.43% of the company’s stock.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.